

# GvHD Hub continues to enhance global knowledge of graft-versus-host disease throughout 2021

Monday 19 July, 2021

**Press Release: Available for Immediate Release**

The [GvHD Hub](#), run by [Scientific Education Support \(SES\)](#) in partnership with the [European LeukemiaNet \(ELN\)](#), has continued to promote significant developments in the treatment and research of graft-versus-host disease (GvHD) throughout Quarter 2 of 2021.

Despite the challenges created by the COVID-19 pandemic, the hub has been further expanding its social media presence and engaging with the global community on all major social networks, helping to improve everyday clinical practice.

**Speaking about the impact the hub has had this year, Mia Hill, IME director at Scientific Education Support, said:**

“The GvHD Hub continues to support the GvHD community. In April, we introduced a new editorial theme on the [latest updates on chronic GvHD treatment](#). In May, the GvHD Hub held its biannual steering committee meeting virtually, which saw very informative discussions on the direction of the hub. New topics to focus on were introduced and novel educational initiatives were discussed, to ensure that the GvHD Hub stays up to date.

This quarter was a busy one in terms of congresses, with the GvHD Hub providing live coverage from a host of virtual events. In April, we attended the Acute Leukemia Forum 2021, and June saw the 2021 ASCO Annual Meeting and the 26th Congress of the European Hematology Association (EHA2021) take place. During these meetings, the GvHD Hub provided live coverage of sessions and produced articles on the cutting-edge research presented by key experts in the field. Having a presence at all these events enable us to share key updates and enhance the knowledge of GvHD, globally.

The GvHD Hub would like to thank our silver level supporters—Incyte and Novartis—for their continued support of the initiative. Last quarter, we were delighted to welcome Syndax (Bronze) and Kadmon (Contributor) as supporters. We would like to extend a special thanks for their support going forward.”

## ENDS

For more information on the GvHD Hub, please visit [gvhdhub.com](https://gvhdhub.com).

For media enquiries or to explore collaboration opportunities, please contact: [secretariat@scientificeducationsupport.com](mailto:secretariat@scientificeducationsupport.com) or [Barry.Connolly@scientificeducationsupport.com](mailto:Barry.Connolly@scientificeducationsupport.com).

## NOTES TO EDITOR

### About graft-versus-host disease (GvHD)

GvHD is a common complication of allo-HSCT and is a major cause of posttransplant mortality and morbidity. It is caused by immune incompatibility between the graft (donor) and recipient tissues. The graft cells recognize the recipient tissues as foreign and mount an immune response against them.

### About the GvHD Hub

The GvHD Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education on GvHD. Our aim is to enhance knowledge of GvHD through the multichannel dissemination of global advances related to its classification, diagnosis, treatment, and management.

The GvHD Hub is the solution for a time-stretched HCP to easily access impactful information that expedites learning and empowers their treatment decisions. Informed by patients, curated by world leaders and endorsed by expert societies the GvHD Hub supports HCPs worldwide.

The GvHD Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world.

**Media:**

**Related Sectors:**

Media & Marketing :: Medical & Pharmaceutical ::

**Scan Me:**



The GvHD Hub is guided by an international [steering committee](#) of world-leading experts in the field of GvHD and is run in partnership with the European LeukemiaNet.

## GvHD Hub Supporters

Funding for our hubs are made possible through financial support from the pharmaceutical industry. ?All content is developed by SES in collaboration with an expert Steering Committee.? All content is independent, and the educational supporters are allowed no influence on the content.?

- Incyte
- Novartis
- Syndax
- Kadmon

If you are interested in becoming a GvHD supporter, please contact [secretariat@scientificeducationsupport.com](mailto:secretariat@scientificeducationsupport.com)

## About Scientific Education Support (SES)

SES is a medical education company with projects such as community physician education through our therapy hubs, community awareness and education through our 'KNOW' education initiatives, and academic researcher education through Entrepreneurs in Clinical Academia (ECA) programs.

Scientific Education Support already has a portfolio of successful websites supporting the advancement of medical education in the field of hemato-oncology, which includes the [Lymphoma Hub](#), [AML Hub](#), [Multiple Myeloma Hub](#), [ALL Hub](#), [MPN Hub](#), and [MDS Hub](#).

## About the European LeukemiaNet

The European LeukemiaNet cooperates with 220 participating centers in 44 countries, with more than 1,000 researchers and clinicians. The objective is to integrate about 120 leading leukemia trial groups (CML, AML, ALL, CLL, MDS, MPN), their interdisciplinary partner groups (diagnostics, treatment research, registry, guidelines), industry, and SMEs across Europe to form a network promoting cooperative research for curing leukemia.

## Company Contact:

### Scientific Education Support

E. [Abbie.Gunn@scientificeducationsupport...](mailto:Abbie.Gunn@scientificeducationsupport.co.uk)

W. [https://www.scientificeducationsuppor...](https://www.scientificeducationsupport.co.uk)

[View Online](#)

### **Additional Assets:**

<https://gvhdhub.com/>

**Newsroom:** Visit our Newsroom for all the latest stories:

<https://www.scientific-education-support.pressat.co.uk>